KALY - Kali-Extracts, Inc. Previews Pending Report On Cannabis Treatment For Lung Disease Study
February 21 2019 - 10:41AM
InvestorsHub NewsWire
KALY – Kali-Extracts, Inc. Previews
Pending Report On Cannabis Treatment For Lung Disease Study
Dallas, TX --
February 21, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc.
(Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today published a second preview of a pending
full report on their long-term, pilot study on the treatment of
Chronic Obstructive Pulmonary Disease (COPD) in primates with
cannabis extracts derived from Kali-Extracts patented cannabis
extraction process. The first preview was published on
February 5, 2019. The full report is expected within the next
2 weeks. The primate study adds to the Kali-Extracts in vitro
genomics study, previously announced, to evaluate the impact of its
pharmaceutical grade cannabis extracts in combination with other
therapies on COPD patients. The
World Health Organization estimates 65 million people worldwide are
afflicted with moderate to severe COPD and GlobalData forecasts
that the COPD treatment market will reach $14.1 billion by
2025.
The primate
study was conducted by Professor Jeffry Osbourn, Ph.D., from the
University of Kentucky and his Biomedical Science Research Group (BSRG).
Professor Osbourn made the following statement in regard to the
research adding to his original statement published on February
5th, 2019:
“We investigated
the effects of a novel, new agent for the oral treatment of lung
diseases like inflammation of the lung airways in nonhuman primates
with chronic pulmonary fibrosis. The new NCM Biotech supplement was
evaluated at 3 separate concentrations and compared to placebo
treated animals. After only 2 weeks of daily oral treatment, a 5
fold dilution of the supplement extract increased respiration rate
by 55%, airway flow rate by 82%, inspiratory airway flow velocity
by 149%, and tidal volume by 38% compared to each animal’s own
control values. Blood pressure and heart rate were not changed by
the compound during this time frame. These large increases in
pulmonary function in fibrotic lungs elicited marked increases in
resting minute ventilation in these animals. A full report of the
detailed data will be available within the next 2 weeks. Larger
dilution (25 fold) had little to no effect on airway or lung
functions. Further evaluation of this oral supplement is planned
for determining the histological and gene regulatory changes in
pulmonary airways, short and long term pharmacological compound
distribution and renal/hepatic handling of the extract as well as
molecular gas chromatography, mass spectroscopy assessment of the
biologically active components. These future experiments are
designed to more closely identify the mechanisms of this improved
overall lung function leading to greatly improved life styles and
activity levels for the large numbers of patients suffering from
chronic pulmonary fibrosis.”
Kali-Extracts, Inc. (“KALY”) is a health and
wellness company set to generate revenue from its patented cannabis
extraction technology through overlapping go-to-market
strategies. KALY is utilizing is patented cannabis extraction
process to develop numerous wellness products both internally and
through partnerships. Similarly, KALY its patented cannabis
extraction technology to develop pharmaceutical products internally
and through partnerships.
KALY has
licensed its extraction process to Puration, Inc. (USOTC:
PURA) (“PURA”) for the production of beverages. With over
$1 million in trailing twelve-month sales, PURA’s sales of EVERx
CBD Sports Water are growing. KALY is now working with PURA
to formulate a 25 MG CBD formula for a new CBD infused water
product. Together, PURA and KALY have signed over a $1
million agreement to produce CBD infused water for Generex
Biotechnology, Inc. (OTCBB:
GNBT). The GNBT product is expected to be on shelves
soon. The PURA and KALY agreement with GNBT is part of a
larger agreement to explore potential pharmaceutical
partnerships.
To learn more
about the company visit https://www.kali-extracts.com/
This press
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), and as such, may involve risks and uncertainties.
These forward looking statements relate to, amongst other things,
current expectation of the business environment in which the
company operates, potential future performance, projections of
future performance and the perceived opportunities in the market.
The company's actual performance, results and achievements may
differ materially from the expressed or implied in such
forward-looking statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214)
210-0459
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Apr 2023 to Apr 2024